Developing and Delivering Treatments that Restore and Preserve Vision for People with Serious Back of the Eye Diseases

Our proprietary SCS Microinjector® is able to precisely administer a wide variety of drug candidates that are specifically formulated to be delivered via suprachoroidal injection. Our unique platform is inherently flexible and intended to work with established medications, new formulations of medicines, as well as future innovations. We have the ability to treat multiple ocular diseases with utility across small molecules and gene therapy.

Our patented, proprietary suprachoroidal space (SCS®) injection treatment approach offers unprecedented access to the back of the eye where sight-threatening disease often occurs. This non-surgical method of administration facilitates more targeted delivery to potentially improve efficacy and compartmentalization of medication while limiting exposure to non-target tissues, such as the vitreous, as compared to other ocular drug administration techniques.

Drug delivery with our SCS Microinjector is a non-surgical, in-office procedure. With thousands of suprachoroidal injections performed to date, the treatment is being adopted into clinical practice.

XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis. XIPERE is the first approved therapeutic delivered into the suprachoroidal space and the first therapy indicated for the treatment of macular edema associated with uveitis. Our XIPERE commercialization partner, Bausch + Lomb, has received a permanent J-Code for the product to support reimbursement by both commercial insurers and government payers.

Diversified Portfolio Targeting Multiple Retinal Disorders

Together with our partners, we are seeking new treatments for multiple blinding eye diseases affecting millions of people worldwide

Benefits for Patients and Physicians Using SCS Microinjector® Delivery

Enhanced Safety

Much lower risk of endophthalmitis as direct contact to immune system vs intravitreal injection

Injectate Flows to Back of the Eye

Reduced risk of floaters, snow globe effect, or other visual disturbances

No Implants or Devices in the Vitreous

Can be easily re-dosed for potentially longer durability

Injection Similar to Intravitreal

Advanced technology requires only a few seconds longer for each injection

Suprachoroidal Injection Provides Targeted Delivery

Abbreviations: SCS: Suprachoroidal Space | RPE: Retinal pigment epithelium

INTELLECTUAL PROPERTY

Our extensive patent portfolio provides us with exclusive rights to commercialize pharmacological agents for treatment of eye diseases via suprachoroidal injection. Our drug candidates, SCS Microinjector and method of drug administration into the SCS are protected by multiple U.S., European and international patents broadly directed to the use of the device, administration of any drug into the SCS by injection, as well as specific product candidates.